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Background
• Bradykinin mediated angioedema is an overarching term
that includes idiopathic angioedema, angiotensin
converting enzyme inhibitor (ACEi) induced angioedema
and hereditary angioedema (HAE).
• This is an emergent condition that must be treated with
the utmost urgency due to the fatal outcomes associated
with the rapid constriction of the throat.
• Bradykinin mediated angioedema is treated differently
from histamine associated angioedema due to its
resistance to corticosteroids and antihistamines.
• HAE and ACEi induced angioedema are treated similarly
but there is a lack of unanimity in the first line
pharmacologic treatment.
• Current treatment options include fresh frozen plasma,
bradykinin-2 receptor antagonists, plasma-kallikrein
inhibitors and C1 esterase inhibitors.
• Tranexamic acid (TXA) has been used for moderate cases
of angioedema but is not well established in the
emergent setting.
• TXA has a 2270-fold lower cost compared to the
preferred agent at this large multicenter hospital
organization, Berinert.

Discussion

Patient Demographics and Clinical Outcomes
Patient Baseline Demographics

Patient Population
• Average patient was a 60-year-old Caucasian male
weighing 101 kg with a history of a home use of an ACEi
with a chief complaint of tongue swelling.
• The mean age was 56 years (range 39-67 years) in the TXA
group and 76 years (range 65-88 years) in the Berinert
group.
• 94.4% of patients in total reported taking a home ACEi
(83.3%) or ARB (11.1%) prior to admission.

Clinical Outcomes

•

Table 2. Clinical Outcomes of Patients

•

Table 1. Patient Baseline Demographics

•

Clinical Outcomes (continued)

•

Purpose

•

• The purpose of this study is to examine whether TXA is a
viable first-line treatment option for bradykininmediated angioedema in the emergency department.

Labs on
admission:

Financial Implications
• The average cost of 1 gram dose of TXA is $6 compared to
$13,617 for Berinert. If one were to estimate an arbitrary
15 incidences of bradykinin mediated angioedema cases in
a year, the average cost of TXA would be $90 compared to
an estimated annual cost of $204,255 of Berinert.
• This is a 2,270-fold price difference.

Objectives

• Determine whether TXA is a viable treatment option for
bradykinin-mediated angioedema
• Evaluate the cost-effectiveness of TXA in comparison to
Berinert
• Examine the incidence of use of TXA versus other
pharmacologic agents used to treat bradykinin-mediated
angioedema
• Identify the optimal or standard dose of oral TXA for
patients presenting to the emergency department with
bradykinin mediated angioedema

Figure 2. Average LOS (days)

Figure 1. Admissions by Department

Study Limitations
• Retrospective chart review
• Disproportionate sizes of cohorts
• The study did not reach the sample size required for
adequate power to assess the primary outcomes of ICU
admissions, intubation rate, and LOS.

Next Steps

Methodology
Figure 3. Comparison of clinical outcomes

• Institutional Review Board (IRB)-approved
• Electronic health record (EHR)-based retrospective chart
review of patients admitted to any of the eight
emergency departments in a large multicenter hospital
organization
• Data was narrowed down by the inclusion criteria and
the “SlicerDicer” tool within EPIC was utilized to extract
the included study population.
• Study period: October 1, 2019 – October 1, 2020
• Inclusion criteria: patients admitted for either ACEi
induced angioedema or HAE and treated with either TXA
or Berinert during their emergency department visit.
• Exclusion criteria: patients <18 years of age, patients
with suspected or confirmed pregnancy, those with an
allergy or intolerance to TXA or Berinert, patients who
were treated with any other drug besides TXA or
Berinert, those with personal or religious objections to
receiving blood products and finally patients with stage
one angioedema.
• Primary outcomes: admission to the ICU, intubation rate
and length of stay (LOS).

Clinical Outcomes
In the TXA cohort, 50% (n=7) patients were admitted to
the hospital with 35.7% of patients in this cohort (n=5)
admitted to the ICU. The remaining patients, 14.3% (n=2)
were admitted to the medicine floor.
The average LOS for patients treated with TXA was 1 day
(range of 1 day) and there was no incidence of bleeding in
this group.
Patients in the Berinert cohort had a 25% incidence of
intubation (n=1). 50% (n=2) of patients were admitted to
the hospital with both patients being admitted to the ICU.
The average LOS for patients treated with Berinert was 2.5
days (range of 1-4 days) and 25% (n=1) patient was
reported to have copious amounts of blood from his
mouth. There was no charting to explain the etiology of
the bleed in this particular patient.
For both cohorts, there was no incidence of mortality,
anaphylaxis or thrombosis.

Financial Comparisons

• This small study showed the potential for utilization of
intravenous TXA as a first line agent for bradykinin-mediated
angioedema.
• A larger study population would need to be assessed to
confirm the benefits of using intravenous tranexamic acid
over a C-1 esterase inhibitor such as Berinert as a first line
agent for bradykinin-mediated angioedema.
• By utilizing a more cost effective and possibly safer agent
such as tranexamic acid, providers may not only improve
outcomes for patients but also reduce costs for a large
multicenter healthcare system.
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